Literature DB >> 12848732

Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.

R N Jones1, T R Anderegg, D J Biedenbach.   

Abstract

The MIC results using a dry-form broth microdilution panel (TREK Diagnostic/Sensititre, Westlake, OH, USA) were validated for AZD2563, a novel oxazolidinone compound. In comparision studies against reference frozen-form panels, the commercial MIC results were the same as the reference calue for 82.7% of organisms and all results were within +/- one log2 dilution. Using 462 organisms, most from three genus groups (enterococci, staphylococci, streptococci), test results indicate that Sensititre MIC values were comparable to the reference test and can be utilized in clinical trials of for routine laboratory use when testing AZD2563 and linezolid, the drug class comparator.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848732     DOI: 10.1046/j.1469-0691.2003.00595.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.

Authors:  Kelley A Gordon; Paul R Rhomberg; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

2.  Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Ronald N Jones; Matthew G Stilwell; Patricia A Hogan; Daniel J Sheehan
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

3.  Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.

Authors:  Ronald N Jones; Nicole M Holliday; Paul R Rhomberg
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.